ライフサイエンスコーパス: CTEPH

1 CTEPH results from persistent obstruction of pulmonary a

2 Reduced and denatured fibrinogen from 33 CTEPH patients was subjected to liquid chromatography-ma

3 dysfibrinogenemias) were observed in 5 of 33 CTEPH patients: Bbeta P235L/gamma R375W, Bbeta P235L/gam

4 brin polymer structure and/or lysis with all CTEPH-associated mutations.

5 s lower in both PAH (2.6 +/- 0.8 mmol/l) and CTEPH (2.7 +/- 0.7 mmol/l) patients when compared to con

6 patients with an E<A transmitral pattern and CTEPH who underwent pulmonary thromboendarterectomy (PTE

7 l limitation after intermediate-risk PE, but CTEPH is infrequent.

8 erectomy remains the treatment of choice for CTEPH and is associated with excellent long-term results

9 We previously reported that fibrin from CTEPH patients is relatively resistant to fibrinolysis i

10 model that replicates the phenotype of human CTEPH.

11 ronic thromboembolic pulmonary hypertension (CTEPH) (RVF, n = 10; no RVF, n = 16).

12 ronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar.

13 ronic thromboembolic pulmonary hypertension (CTEPH) develops after acute pulmonary thromboembolism is

14 ronic thromboembolic pulmonary hypertension (CTEPH) is a rare but debilitating and life-threatening c

15 ronic thromboembolic pulmonary hypertension (CTEPH) is a rare, debilitating, and life-threatening dis

16 ronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel of venous thromboembolism with

17 ronic thromboembolic pulmonary hypertension (CTEPH) undergoing invasive treatment.

18 ronic thromboembolic pulmonary hypertension (CTEPH) was confirmed in 4 (2.1%) versus 6 (3.2%) cases (

19 ronic thromboembolic pulmonary hypertension (CTEPH) will be accelerated by an animal model that repli

20 ronic thromboembolic pulmonary hypertension (CTEPH), but persistent pulmonary hypertension after PTE,

21 ronic thromboembolic pulmonary hypertension (CTEPH), not all patients have surgically accessible dise

22 ronic thromboembolic pulmonary hypertension (CTEPH).

23 ronic thromboembolic pulmonary hypertension (CTEPH).

24 ronic thromboembolic pulmonary hypertension (CTEPH).

25 sion pressure waveform analysis may identify CTEPH patients at risk for persistent pulmonary hyperten

26 ulmonary vascular resistance, might identify CTEPH patients with significant distal, small-vessel dis

27 In CTEPH, LV diastolic function often appears abnormal.

28 andomized comparison with medical therapy in CTEPH patients who are not surgical candidates.

29 tly improved PVR in patients with inoperable CTEPH and was well tolerated.

30 ng-term outcomes in patients with inoperable CTEPH or persistent or recurrent pulmonary hypertension

31 For patients with inoperable CTEPH, various medical and interventional therapies are

32 ent of patients enrolled in an international CTEPH registry was investigated.

33 These data indicate that PTE offers most CTEPH patients substantial improvement in survival, func

34 nical presentation, operable and nonoperable CTEPH patients may have distinct associated medical cond

35 brin may be implicated in the development of CTEPH after acute thromboembolism.

36 iography usually reveals typical features of CTEPH, including mosaic perfusion, part or complete occl

37 gen) might contribute to the pathogenesis of CTEPH.

38 to reproduce much of the known phenotype of CTEPH, including the pivotal pathophysiological role of

39 At the time of CTEPH diagnosis, 37.7% of patients initiated at least 1

40 The diagnostic work-up to detect or rule out CTEPH should include ventilation-perfusion scintigraphy,

41 Patients with suspected CTEPH should be referred to a specialist centre for righ

42 In the CTEPH group, LDL-C increased (from 2.6[2.1-3.2] to 4.0[2

43 gical understanding of how PE transitions to CTEPH in human treatments.

44 Bbeta P235L was found in 3 unrelated CTEPH patients.

45 rial assessed macitentan in 80 patients with CTEPH adjudicated as inoperable.

46 /A is consistently abnormal in patients with CTEPH and increases post-PTE.

47 lmonary artery hypertension in patients with CTEPH and is associated with long-term improvement in Ne

48 Patients with CTEPH and Rup value <60% appear to be at highest risk.

49 ntricular pressure overload in patients with CTEPH causes abnormal LV diastolic filling.

50 relaxation pattern observed in patients with CTEPH is not solely the result of geometric effects of R

51 dynamic data in 39 consecutive patients with CTEPH over the age of 30 (55 +/- 11 years) with mean pul

52 The LV of patients with CTEPH with RVF also exhibited ERP prolongation (306 +/-

53 osed (</=6 months) consecutive patients with CTEPH, from February 2007 until January 2009.

54 iguat may be used long term in patients with CTEPH.

55 Not all patients presenting with CTEPH have a history of clinically overt pulmonary embol

56 age, 51.8 years; range, 14 to 75 years) with CTEPH underwent BPA; they averaged 2.6 procedures (range